drugset / Trial / NCT00427999
Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.
Timeline
- Start
- 2007-02
- Primary completion
- 2015-06
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Dexamethasone | Small molecule | 1 mg | Oral |
| Background | Etoricoxib | Small molecule | 60 mg | Oral |
| Background | Imatinib | Small molecule | 400 mg | Oral |
| Background | Pioglitazone | Small molecule | 60 mg | Oral |
| Background | Treosulfane | Unknown | 500 mg | Oral |